What Is Hairy Cell Leukemia and How Do Families Plan for End of Life?
By CRYSTAL BAI •
The short answer: Hairy cell leukemia (HCL) is a rare, slow-growing B-cell leukemia that is highly treatable in most patients with cladribine or pentostatin. However, relapsed/refractory HCL — particularly with the BRAF V600E mutation — can become treatment-resistant, requiring palliative care and end-of-life planning.
Understanding Hairy Cell Leukemia
HCL accounts for 2% of all leukemias and is characterized by B cells with hair-like cytoplasmic projections. Classic HCL harbors the BRAF V600E mutation in approximately 90% of cases. It typically presents with pancytopenia (low blood counts), splenomegaly, and monocytopenia.
Excellent Initial Treatment Response
HCL is highly responsive to purine analogues — cladribine (2-CDA) and pentostatin achieve complete remission in 75–91% of patients. Many patients remain in long-term remission after a single course of therapy, making HCL one of the more manageable leukemias initially.
Relapsed and Refractory HCL
While most patients achieve initial remission, relapses occur and become increasingly difficult to treat with each relapse. BRAF inhibitors (vemurafenib) and combinations with MEK inhibitors are active in BRAF-mutated relapsed HCL. Moxetumomab pasudotox is FDA-approved for relapsed/refractory HCL.
When HCL Becomes Treatment-Refractory
A small subset of HCL patients — usually with multiple relapses and comorbidities — eventually reach a point where no effective treatment remains. At this stage, hospice-level comfort care and end-of-life planning become the priority.
Frequently Asked Questions
Is hairy cell leukemia curable?
Most HCL patients achieve long-term remission with cladribine or pentostatin, and some may be effectively 'cured.' However, relapses occur and can become increasingly treatment-resistant over time.
What is the BRAF V600E mutation in hairy cell leukemia?
BRAF V600E is a mutation found in approximately 90% of classic HCL cases. It is a therapeutic target — BRAF inhibitors (vemurafenib) are active in BRAF-mutated HCL and are used for relapsed disease.
Can a death doula help with HCL end-of-life planning?
Yes — for the subset of HCL patients who develop treatment-refractory disease, death doulas provide advance care planning support, legacy work, and emotional presence during this often-unexpected disease progression.
What are the symptoms of advanced hairy cell leukemia?
Advanced HCL can cause severe cytopenias (anemia, low platelets, neutropenia), infections, splenomegaly, and fatigue. Palliative transfusions and infection management are important comfort measures.
Renidy connects grieving families with compassionate death doulas and AI-powered funeral planning tools. Try our free AI funeral planner or find a death doula near you.